Safety Monitoring of Omaveloxolone in Friedreich Ataxia: Results from One Year of Clinical Treatment

Abstract Introduction Omaveloxolone, the only approved medication for Friedreich ataxia (FRDA), is an NRF2 activator available since July 2023. We examined safety monitoring of omaveloxolone administration over the first 12 months of administration. Methods We recorded baseline and follow-up serum t...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Katherine Gunther, Victoria Profeta, Medina Keita, Courtney Park, McKenzie Wells, Sonal Sharma, Kimberly Schadt, David R. Lynch
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Adis, Springer Healthcare 2025-04-01
Schriftenreihe:	Neurology and Therapy
Schlagworte:	Brain natriuretic peptide Mitochondria transaminase Movement disorder Omaveloxolone
Online-Zugang:	https://doi.org/10.1007/s40120-025-00749-3
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!